Literature DB >> 27334841

Luteolin induces cholangiocarcinoma cell apoptosis through the mitochondrial-dependent pathway mediated by reactive oxygen species.

Natthawan Kittiratphatthana1, Veerapol Kukongviriyapan1,2, Auemduan Prawan1,2, Laddawan Senggunprai1,2.   

Abstract

OBJECTIVES: To investigate the apoptosis-inducing effect and underlying mechanisms of luteolin in cholangiocarcinoma (CCA) cells.
METHODS: Cell viability was determined by sulphorhodamine B. Apoptosis was detected using acridine orange/ethidium bromide dye staining and annexin V/PI staining followed by flow cytometry. The effect of luteolin on the oxidative status of CCA cells was evaluated by measuring intracellular reactive oxygen species (ROS) levels using the dihydroethidium method and quantifying glutathione levels. The mitochondria transmembrane potential (ΔΨm) was examined through JC-1 staining. The protein levels were determined by Western blot. Caspase activity was determined using specific fluorogenic substrates. KEY
FINDINGS: Luteolin decreased KKU-100 CCA cells' viability by induction of apoptosis. Luteolin treatment increased ROS production and decreased glutathione levels. These changes were associated with the decrease of Nrf2, γ-glutamylcysteine ligase and heme oxygenase-1 proteins. Moreover, luteolin induced mitochondrial depolarization, which was accompanied by the release of cytochrome c and a decrease of Bcl-2 and Bcl-XL proteins. Pretreatment with antioxidants, 4-hydroxy-TEMPO and N-acetyl-L-cysteine significantly prevented luteolin-induced CCA cell death and loss of ΔΨm. In addition, luteolin induced the activation of caspase-9 and caspase-3.
CONCLUSIONS: Luteolin exerts its pro-apoptotic action partly through generating intracellular ROS that then contributes to the activation of mitochondria-mediated apoptotic cell death.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  apoptosis; cholangiocarcinoma; luteolin; mitochondria; reactive oxygen species

Mesh:

Substances:

Year:  2016        PMID: 27334841     DOI: 10.1111/jphp.12586

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells.

Authors:  Bu-Chun Zhang; Zhi Li; Wu Xu; Chu-Han Xiang; Yan-Feng Ma
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.

Authors:  Sirinapha Klungsaeng; Veerapol Kukongviriyapan; Auemduan Prawan; Sarinya Kongpetch; Laddawan Senggunprai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-23       Impact factor: 3.000

3.  Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.

Authors:  Xiangcui Chen; Qipeng Wu; Yueming Chen; Jiahao Zhang; Huachao Li; Zhicheng Yang; Yang Yang; Yanchao Deng; Luyong Zhang; Bing Liu
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 4.  Anticancer activity of flavonoids accompanied by redox state modulation and the potential for a chemotherapeutic strategy.

Authors:  Yongkyu Lee; Jehyung Lee; Changbaek Lim
Journal:  Food Sci Biotechnol       Date:  2021-03-20       Impact factor: 2.391

5.  All-trans-retinoic acid induces RARB-dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells.

Authors:  Siriwoot Butsri; Veerapol Kukongviriyapan; Laddawan Senggunprai; Sarinya Kongpetch; Auemduan Prawan
Journal:  Oncol Lett       Date:  2022-04-14       Impact factor: 3.111

6.  Luteolin Treatment Protects against Renal Ischemia-Reperfusion Injury in Rats.

Authors:  Xin Hong; Xiaojing Zhao; Gang Wang; Zhengliang Zhang; Honghong Pei; Zhong Liu
Journal:  Mediators Inflamm       Date:  2017-11-21       Impact factor: 4.711

Review 7.  Nrf2 in cancers: A double-edged sword.

Authors:  Shijia Wu; Hong Lu; Yongheng Bai
Journal:  Cancer Med       Date:  2019-03-30       Impact factor: 4.452

8.  Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway.

Authors:  Kuen-Jang Tsai; Hsin-Yi Tsai; Chin-Chuan Tsai; Tai-Yu Chen; Tsung-Hua Hsieh; Chun-Lin Chen; Lulekiwe Mbuyisa; Yaw-Bin Huang; Ming-Wei Lin
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

Review 9.  Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics.

Authors:  Kesara Na-Bangchang; Tullayakorn Plengsuriyakarn; Juntra Karbwang
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-14       Impact factor: 2.629

10.  Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity.

Authors:  Shiva Prasad Kollur; Shashanka K Prasad; Sushma Pradeep; Ravindra Veerapur; Sharanagouda S Patil; Raghavendra G Amachawadi; Rajendra Prasad S; Ghada Lamraoui; Abdulaziz A Al-Kheraif; Abdallah M Elgorban; Asad Syed; Chandan Shivamallu
Journal:  Biomolecules       Date:  2021-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.